PREPRINT: Mechanisms of Motoric Cognitive Risk - hypotheses based on

a systematic review and meta-analysis of longitudinal cohort studies of older

3 adults

1

2

4

7

13

17

20

- 5 Donncha S. Mullin MBChB MRCPsych, 1-4* Alastair Cockburn MBChB, 4 Miles Welstead MSc, 5
- 6 Michelle Luciano PhD, ⁵ Tom C. Russ PhD MRCPsych, ¹⁻⁵ Graciela Muniz-Terrera PhD^{2,3}
- 8 Alzheimer Scotland Dementia Research Centre, University of Edinburgh;
- 9 ^{2.} Edinburgh Dementia Prevention Group, University of Edinburgh;
- Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh;
- 11 4. NHS Lothian, Royal Edinburgh Hospital, Edinburgh;
- 12 5. Lothian Birth Cohorts, Department of Psychology, University of Edinburgh.
- * Dr Donncha S. Mullin, Division of Psychiatry, University of Edinburgh, Kennedy Tower,
- 15 Royal Edinburgh Hospital, Morningside Terrace, Edinburgh, EH10 5HF, UK
- 16 Telephone: +44 (0)131 537 6000; Email: <u>D.Mullin@ed.ac.uk</u>
- 18 Manuscript statistics: Main text of 5000 words, abstract of 150 words, 4 figures, 3 tables,
- 19 research in context 139 words, 52 references, 4 supplementary tables, 2 supplementary boxes.
- 21 Contributions: DSM, TCR and GMT generated the idea for the present manuscript. DSM
- conducted the literature search; screened the titles, abstracts, and full texts; extracted data and
- 23 performed quality assessment; carried out the meta-analyses; drafted the manuscript; and is the
- 24 guarantor. AC acted as independent second reviewer; independently extracted all the data and
- 25 assessed the reporting quality of all full texts. MW assessed the search and screening process. All
- authors edited the manuscript and meet authorship criteria. No others meeting the criteria have
- 27 been omitted.
- 29 Funding: The present manuscript received no direct funding. All funded researchers are
- independent of their funders with payments to institution. AC has no funding to declare. DSM is
- 31 undertaking a PhD Clinical Research Fellowship funded by a one-off grant from the Masonic
- 32 Charitable Foundation and the Royal College of Psychiatrists, United Kingdom. MW is funded
- by an Age UK [MR/M01311/1] grant for PhD studentship. ML is funded by a Biotechnology
- 34 and Biological Sciences Research Council (BBSRC) project grant and is a previous recipient of
- 35 the Moray Award for travel from University of Edinburgh. TCR is Principal Investigator 2021–
- 36 2024 £1,518,000 grant, Chief Scientist Office: "NRS Neuroprogressive and Dementia Network"
- 37 2021–22 £216,666 grant, UKRI: "Sharing the diagnosis of dementia in the post-Covid clinic:
- patient and practitioner perspectives" 2019-21 £10,394 Catalytic grant, CSO: "Playlist for Life:
- 39 Can personalised music be rapidly implemented in care homes as a non-pharmacological
- 40 intervention for dementia?" 2017–18 £56,519 grant, NERC-MRC-CSO: "Modelling historical air
- 41 pollution and dementia/cognitive decline towards a life course approach" 2016-2021 £750,000
- 42 grant from Alzheimer Scotland for Phase 2 of the Alzheimer Scotland Dementia Research
- 43 Centre Co-investigator 2019-2021 £733,246 Research grant, MRC: "Brain imaging and cognitive
- 44 ageing in the Lothian Birth Cohort 1936: IV" 2017-18 \$40,000 from the Japan Agency for
- 45 Medical Research and Development / New York Academy of Sciences Interstellar Initiative.
- 46 TCR occasionally completes medicolegal reports for Solicitors in Edinburgh. These payments are

made to him but relate solely to his clinical work and not the academic work under review. TCR receives NHS study leave expenses (travel, accommodation, and registration). GMT is funded by the Medical Research Council methodology board and received consulting fees for an NIH-funded grant.

Declarations of interest: MW is vice-chair of the Scotland Research Ethics Committee. TCR has participated on the Alzheimer's Society and Alzheimer Scotland Advisory Boards - no payment. No other authors claim any disclosure.

Selected aspects of the present manuscript were presented in preliminary form as a poster at the 2021 Alzheimer's Association International Conference, online.

Abstract

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

We aimed to refine the hypothesis that Motoric Cognitive Risk (MCR), a syndrome combining measured slow gait speed and self-reported cognitive complaints, is prognostic of incident dementia and other major causes of morbidity in older age. We propose mechanisms on the relationship between motor and cognitive function and describe a roadmap to validate these hypotheses. We systematically searched major electronic databases from inception to August 2021 for original longitudinal cohort studies of adults aged ≥60 years that compared an MCR group to a non-MCR group with any health outcome. Fifteen cohorts were combined by metaanalysis. Participants with MCR were at an increased risk of cognitive impairment (adjusted hazard ratio [aHR] 1.76, 95%CI 1.49-2.08; I²=24.9%), dementia (aHR 2.12, 1.85-2.42; 33.1%), falls (adjusted Relative Risk 1.38, 1.15-1.66; 62.1%), and mortality (aHR 1.49, 1.16-1.91; 79.2%). The prognostic value of MCR is considerable and mechanisms underlying the syndrome are proposed. Keywords: Motoric cognitive risk, gait, dementia, review, meta-analysis, mechanism, pathophysiology, falls, mortality, subjective cognitive complaint, prognostic, prevention Systematic review registration: PROSPERO CRD42020225183.

1. Narrative

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

1.1 Central question Can a gait-based syndrome, Motoric Cognitive Risk (MCR), predict dementia and other agerelated negative health outcomes? If so, what are the possible underlying mechanisms? 1.2 Objective This paper is a proposal for an update of the Hypothesis on the Motoric-cognitive Mechanism in Neurodegeneration-Dementia-Alzheimer¹ syndrome (abbreviated hereafter as the Hypothesis) based on a thorough systematic review and meta-analysis of the evidence. The present work intends to: (1) promote new thinking about the prognostic value of MCR in dementia and other major causes of morbidity in older age; and (2) propose shared mechanisms between MCR and neurodegeneration and outline a roadmap for further work to validate these hypotheses. This report aims to synthesize and critique current evidence on MCR and describe challenges to the MCR concept and the use of MCR as a clinical tool. 1.3 Current knowledge As there are still no effective treatments for dementia, any biomarker that supports early identification of high-risk individuals would allow time for lifestyle modification, planning for future care needs, and could ultimately contribute to a reduction in overall prevalence of dementia. Slow gait speed and self-reported cognitive complaints show potential to be such biomarkers as they are some of the earliest reported precursors in the pre-clinical stage of dementia, occurring 10-15 years before dementia diagnosis. ¹² Motoric cognitive risk (MCR) syndrome is a high-risk state combining objective (measured) slow walking speed and subjective

(self-reported) cognitive complaint in those able to ambulate and in the absence of dementia.³

First defined by Verghese in 2013⁴, MCR has incremental predictive ability over either slow gait or cognitive complaint alone.⁵ Gait is a complex task requiring coordination between widespread brain regions, therefore MCR may reflect neurodegeneration occurring in the preclinical stage of dementia. Imaging studies in the MCR field indicate atrophy of executive function areas (frontal and pre-frontal lobe networks).⁶

The only existing meta-analysis of MCR⁷ found that MCR predicts cognitive impairment and dementia. However, this meta-analysis had significant methodological limitations, including pooling the results of different effect measures (e.g., hazard ratios and odds ratios) and, focusing on the term "MCR", thus only including studies published from 2013 onward and excluding

on the term "MCR", thus only including studies published from 2013 onward and excluding earlier papers examining the same construct without naming it as such. We address these limitations in our study. Other studies report that MCR identifies those at risk of falls, ⁸⁻¹⁰ postfalls hip fractures, ⁹ disability, ¹¹ and mortality, ^{12,13} but these studies have not yet been pooled in a

meta-analysis. Other non-systematic MCR reviews focused on risk factors for developing MCR¹⁴

or aimed to give a more general overview of the MCR construct.6

1.4 Knowledge gap and importance of this study

Important conditions such as dementia or falls are projected to affect such a large number of people over the next 30 years that even small reductions in the incidence – or delaying the age of onset which would have the same result – are likely to have significant effects on numbers of people affected and consequently the huge associated public health costs. ^{5,14} Could there be shared mechanisms explaining the association of MCR with both these outcomes? If so, identifying and targeting these mechanisms could reduce the prevalence of these major causes of morbidity and mortality in older adults. Furthermore, if a quick, inexpensive, and easy-to-measure clinical construct could reliably identify people at high risk of developing either or both

dementia and falls, along with other adverse health outcomes such as cognitive impairment and mortality, it would be an important public health tool and would be equally implementable in low-to-middle income countries. Our study addresses this knowledge gap and proposes hypotheses on the underlying mechanisms.

1.5 Limitations

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

We were unable to obtain raw data from every eligible study to allow for calculation of a comparable summary effect measure for each study for inclusion in the meta-analysis – an individual participant meta-analysis. Therefore, some studies had to be left out of the pooled result, reducing the overall power. We believe this important compromise ensures our findings are as valid and reliable as possible based on the published literature while avoiding potential significant delays to undertaking this novel work. Most studies in our review had a degree of risk of bias (ROB) due to how they managed missing data and confounding factors, and a lack of generalizability (section 2.1.6). These are common limitations in cohort studies and partly explain why they are lower down the hierarchy of evidence compared to randomized controlled trials. We accounted for substantial heterogeneity in the mortality outcome by downgrading our Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty assessment for inconsistency (see section 2.2.5). Although some might avoid pooling our mortality data due to statistical heterogeneity, we believe the summary data provide an important global perspective on MCR.¹³ There is a relatively small number of studies for each health outcome in the meta-analysis, meaning that statistical tests for publication bias lacked power to detect real asymmetry from chance, although visual inspection of funnel plots is reassuring (section 2.3.5). Finally, dementia is a clinical diagnosis, but in the studies included it was often determined using surrogate markers such as scores in cognitive tests, increasing heterogeneity and decreasing the generalizability of our findings. This is a common issue in dementia research

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

analysis.

using cohort data. Reassuringly, the results of studies that diagnosed dementia using clinical criteria^{4,5} were consistent with those using surrogate markers. ^{11,15} 1.6 Discussion Our results for risk of cognitive impairment and dementia in participants with MCR at baseline were consistent with the only existing meta-analysis on the topic. This earlier meta-analysis reported that individuals with MCR were at a 70% increased risk of developing cognitive impairment (adjusted Hazard Ratio [aHR] 1.70, 95%CI 1.46-1.98) and a 150% increased risk of developing dementia (aHR 2.50, 95%CI 1.75-2.39). The slight differences reflect our inclusion of new studies and two major strengths of our study, namely our decisions to only pool summary effect measures of the same type and to always use the most adjusted effect measure reported. Accordingly, our findings have reduced confounding and are likely to be more conservative. Furthermore, by focusing on the term "MCR", the previous meta-analysis only included studies published from 2013 onward, unlike our search which captured any study combining slow gait and subjective cognitive complaint since database inception. Our paper makes methodological advances on the existing meta-analysis with regards to cognitive impairment and dementia outcomes, and it is the first to meta-analyze MCR studies reporting on falls and mortality outcomes. As MCR is a recently defined construct, more research is needed to increase certainty in each of our findings, particularly falls prediction. Other

outcomes more likely in those with MCR at baseline include recurrent falls, post-falls hip

fractures, and disability, but these outcomes require further research to allow for robust meta-

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

1.6.1 Hypotheses on mechanisms underlying MCR Interactions between MCR, poor brain health, falls, and increased mortality are likely due to a range of biological, psychological, and social mechanisms. Causality is likely to be bidirectional, and the mechanisms may be multifactorial. There is unlikely to be one, unifying mechanism linking MCR with these negative health outcomes, but, based on recent evidence, we propose hypotheses to explain some of the potential underlying biological mechanisms. Epidemiological and clinical MCR prevalence increases with age with rates of 8.9% in the 60-74 years group and 10.6% in the ≥75 years group. MCR may increase the risk of dementia, falls and mortality by contributing to geriatric syndromes such as delirium, depression, and medication mismanagement. Lower education is associated with increased risk of MCR^{5,13,16} and is an established risk factor for dementia. Low physical activity is another lifestyle risk factor shared by MCR with dementia, falls, disability, and increased mortality. 11,13,17 Reduced concentration and psychomotor retardation are well-recognized symptoms of depression, so it is no surprise that depression has been associated with MCR. 18 Personality traits such as neuroticism 19 have also been associated with MCR, which may in part be due to an increased likelihood in this population to report subjective cognitive complaint. Pilot trials to improve executive function by cognitive training, dual-task 'walking while talking', or brain stimulation have improved gait speed.⁶ Neuropathology Emerging data suggest that both neurodegenerative and vascular changes may contribute to progression to dementia in those with MCR.²⁰ It is widely accepted that cerebral small vessel disease (SVD) is an important cause of dementia and it is estimated that over one third of dementias could be prevented by preventing stroke.²¹ Lacunar infarcts in the frontal lobe were

associated with MCR even after adjusting for vascular risk factors and presence of white matter

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

22.7

228

229

hyperintensities (adjusted Odds Ratio (aOR): 4.67, 95% CI: 1.69-12.94). 22 SVD is also a significant contributor to risk of falling and SVD, especially in the frontal lobes, and has been linked to increased mortality. 12 However, adults free of dementia with slow gait had associated amyloid β brain deposition, independent of underlying vascular change.²³ Cognition and gait share many other risk factors such as cardiovascular disease and diabetes mellitus²⁴ so it is no surprise that a pooled meta-analysis found that MCR was associated with both of these chronic conditions, as well as hypertension and stroke.²⁵ These findings support our hypothesis that a vascular mechanism may underlie the pathophysiology of MCR syndrome. Neuroimaging and neurophysiology A 2019 review reported that MCR was associated with lower gray matter volume in the premotor and prefrontal cortices, but had no significant association with white matter abnormalities. The authors concluded that the pathophysiology of MCR was more likely due to neurodegenerative rather than ischemic lesions. This conclusion was admittedly based on a small number of imaging studies and it was hypothesized that MCR detects individuals at such an early stage of the disease process leading to dementia that the consequences of the vascular component may not yet be detected. Furthermore, MCR was associated with frontal lacunar infarcts in a study of 139 older adults in India.²² Genetics The first study to investigate individual-level genetic burden in relation to a predementia syndrome examined the polygenic inheritance of MCR in a sample of 4,915 older individuals.²⁶ The authors examined nine phenotypes associated with MCR and found that obesity-related genetic traits increase the risk of MCR syndrome. Obesity in older adults is an established risk factor in falls, disability and increased mortality.^{27,28}

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

A prospective examination of inflammatory cytokine genes found that polymorphisms which lead to over-expression of the anti-inflammatory cytokine Interleukin-10 (IL-10) are associated with increased MCR incidence.²⁹ While this makes any shared neuroinflammatory pathway between MCR and dementia less probable, an over-expression of IL-10 points toward a proamyloidogenic hypothesis of cognitive decline.²⁹ Early work in mice models found that IL-10 expression leads to increased amyloid β accumulation and reduction in synaptic proteins as well as increasing expression of APOE and suppressed phagocytosis of β-amyloid by microglia.³⁰ This link between APOE and MCR is perhaps unsurprising as the APOE \$\pi 4\$ allele was independently associated with increased risk of gait speed decline and disability in older men.³¹ Cellular mechanisms No specific mechanistic work on MCR at the cellular level has been performed to date. However, emerging evidence on the effects of Alzheimer's disease pathology on motor neuron function in transgenic mice merit consideration. For example, many studies have reported on the impaired motor performance such as beam walking and significant motor neuron axonopathy in transgenic mice with β-amyloid mutations. 1,32 It will be fascinating to assess if future studies treating developed or preventing Alzheimer's disease pathologies improves or prevents further declines of motor function.1 1.7 Major challenges for the Hypothesis First, the definition of MCR requires standardization to allow for better comparison of MCR prevalence rates and prognostic value across populations. The range of methods for diagnosing subjective cognitive complaint highlights the need for a consistent definition of MCR in future studies.

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

Early work by Verghese et al.4 found that MCR was better at predicting vascular dementia than Alzheimer dementia, but more recent work in an independent cohort¹⁵ found conversely that MCR was better at predicting Alzheimer's dementia than non-Alzheimer's dementia. This challenges the premise that early upstream vascular alterations degrade the brain structures shared by cognitive and motor function systems, namely frontal and prefrontal motor cortex. 20,21 1.8 Conclusions and next steps The motoric-cognitive hypothesis of neurodegeneration does not seem to have one unifying underlying mechanism, so future steps to elucidate these will require a multidisciplinary approach exploring the issue using complementary techniques. 1. The relative contributions from cortical motor regions to neuropsychological tests that comprise part of the clinical diagnosis of dementia remain to be addressed.¹ 2. Longitudinal studies of at-risk populations with genetic, neurophysiological, neuroimaging, or other biomarkers and pathological validation will help determine the progress of motor and cognitive impairment in dementia.³³ 3. A large-scale discovery genome-wide association study of MCR is an important step to identify underlying biological mechanisms of MCR. This would identify targets for further investigation and possibly treatment to reduce MCR and ultimately dementia, falls, disability, and excess mortality. The generation of a reliable MCR polygenic risk score might have clinical utility for early prediction, and thus prevention, of those at risk of MCR.

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

4. Interventional trials are important to assess whether targeting slow gait and subjective cognitive impairment delays or reverses MCR, and whether this reduces transition to cognitive impairment, dementia, falls, and excess mortality. 2. Consolidated Results and Study Design 2.1 Methodology This systematic review was conducted following the updated guidelines of Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA 2020)³⁴ and the meta-analysis followed the Meta-Analyses of Observational Studies in Epidemiology (MOOSE) guidelines.³⁵ The protocol was pre-registered in the international prospective register of systematic reviews (PROSPERO CRD42020225183). 2.1.1 Search strategy We searched the AMED, APA PsychInfo, CINAHL, Cochrane, EMBASE and Ovid MEDLINE databases from conception to 20/08/2021, then carried out a backwards and forwards citation search with no language or publication date restrictions. The search strategy was devised iteratively with support from an academic librarian, and the strategy was peer reviewed using the Peer Review of Electronic Search Strategies (PRESS) checklist.³⁶ The full search strategy is in supplementary table 1.

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

2.1.2 Eligibility criteria We used the PICOT (Population; Intervention; Comparator; Outcome; Timing/Type) system to design our review question (supplementary box 1).³⁷ In summary, we examined longitudinal cohort studies of community-based adults aged ≥60 years with an MCR group compared to a non-MCR group for any health outcome with a minimum of one year follow-up. Only peerreviewed full-text articles were included in the meta-analysis and synthesis. 2.1.3 Screening and selection Two authors (DM and AC) independently reviewed all titles then all included abstracts using Covidence software.³⁸ If the study appeared to meet the selection criteria, the same two investigators independently reviewed the full text. Discrepancies were resolved through open discussion and verified by a third author when necessary. 2.1.4 Data collection process We iteratively designed a bespoke data extraction tool based on the CHARMS-PF (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies, adapted for prognostic factors) template³⁷, which two authors (DM and AC) used independently to extract data from eligible studies (supplementary table 2). We then compared the extracted data and resolved any discrepancies through discussion and referring to the study in question. The combined data extraction tool was then double-checked for accuracy. Whenever study details were unclear, we contacted study authors for further information.

2.1.5 Data items

We extracted the following data for the exposure variable (MCR): slow gait measurement protocol, average gait speed, subjective cognitive complaint measurement method and MCR prevalence rate. For our outcome variables, we recorded method of measurement as well as the most adjusted model results of any health outcome result, whether reported as adjusted hazard ratio (aHR), adjusted odds ratio (aOR), or adjusted relative risk (aRR), and their corresponding 95% confidence intervals (CI) and p-values, if available. Unadjusted model results were not reported frequently enough to allow meaningful comparison on synthesis. To inform assessment of residual confounding, we recorded the covariates adjusted for in each model. Where an outcome was reported over various follow-up timepoints we selected those timepoints most common across studies to minimize meta-analysis heterogeneity. Other data items extracted included, author name, year, country, cohort, size, the study design, and participant characteristics.

2.1.6 Study quality and risk of bias assessment

We performed a ROB assessment, using an expanded version of the Quality In Prognosis Studies (QUIPS) tool recommended by the Cochrane Prognosis Methods Group to assess ROB in prognostic factor studies.³⁷ We generated a summary ROB plot illustrating the overall ROB of the literature base, and a ROB traffic light plot to illustrate the ROB of each study. The ROB assessments were incorporated into our meta-analysis at the grading of evidence stage.

2.2 Meta-analysis

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

2.2.1 Eligibility for each synthesis We tabulated the study outcome characteristics and compared each against our planned outcome to ensure that the study outcome was valid. We only included in the meta-analysis those studies with outcomes which were judged satisfactory by our clinical content experts. Only health outcomes reported from at least three cohorts were included in the meta-analysis, to ensure appropriate synthesis. 2.2.2 Effect measures We used aHR and 95% CI to synthesize studies reporting cognitive impairment, dementia, and mortality outcomes, and aRR and 95% CIs to synthesize studies reporting falls as the outcome. These were the effect measures most reported in eligible studies for each of these outcomes, thus allowing inclusion of most studies. When a study reported the effect measure in a way incompatible with our analysis, we contacted the authors to request data to allow for our own calculation (e.g., aHR) or we converted the effect measure (e.g., aOR to aRR), if possible and appropriate, based on methods suggested by Tierney. 39 If these attempts were not successful, we omitted the study from our meta-analysis to avoid comparing different effect measures in the one analysis. In all cases, only the most adjusted effect measures were used. 2.2.3 Synthesis methods We log-transformed our effect measures and their 95% CIs to make them normally distributed, an assumption of our meta-analysis model. We then calculated log standard error using the methods described in the Cochrane Handbook v6.2.40

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

We used a random-effect model (REM) to allow for within-study sampling error and betweenstudies variability due to varying study characteristics. The relative lack of small studies supported our decision to use the REM approach (as smaller studies receive larger weights in REM in comparison to fixed-effect modelling). The degree of heterogeneity was calculated using a restricted maximum-likelihood estimator, following recent guidance. 40 The extent and impact of between-study heterogeneity were visually displayed in forest plots and reported as the tausquared and I-squared statistic, accompanied by 95% CIs to judge our confidence about these metrics. I-squared was chosen over Cochrane's Q to better account for the small number of studies in each analysis. Prediction intervals are included in the forest plots to illustrate the range for which we can expect the effects of future studies to fall, based on our present evidence in the meta-analysis. Prediction intervals help overcome any limitations of the I-squared and tausquared methods. 41 Meta-analysis was performed by one author in R (version 4.0.2) using the metafor (2.4.0) and dmetar (0.0.9) packages.⁴² We tabulated our study characteristics structured by outcome domain, ordered from low to high ROB to orientate readers to the most robust evidence (table 1). The results of the meta-analyses are displayed in forest plots for each outcome, displaying the effect estimates and confidence intervals of each study and the summary estimate. The plots are ordered by study weight to highlight any patterns in the data.

2.2.4 Assessing publication bias or outcome reporting bias

We produced funnel plots for meta-analysis of MCR for each health outcome to allow for visual assessment of small-study effects. These were assessed for asymmetry using Egger's test. To assess outcome reporting bias, two reviewers independently compared the outcomes reported in the methods and results sections of the studies.

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

2.2.5 Certainty assessment methods Our default starting position regarding certainty in the level of evidence was in keeping with the Cochrane guidance to generally regard evidence from sound observational studies as low quality. 40 We modified the GRADE considerations adapted for prognosis research as recommended by Huguet⁴³ to assess the certainty of the body of evidence as it related to the studies included in the meta-analyses for each outcome. See section 3.1 and supplementary box 2 for full details. 2.3 Results 2.3.1 Study selection We found 705 records on database searching, following de-duplication. We sought retrieval of full-text reports for 94. We included 15 studies from the databases search, 4,5,8-13,15-17,44-47 with 11 of these proving eligible for meta-analysis. We then performed backwards and forwards citation searching by reviewing the reference list of these studies, as well as those of three reviews^{7,14,48} and one editorial paper³³ on MCR. Of the 1800 records found this way, we reviewed full-text reports for 35 but included no additional papers. One longitudinal study which appeared to meet inclusion criteria was excluded as the MCR group defined using slow gait speed as a criteria was not followed up longitudinally.3 Figure 1 shows the PRISMA flow diagram of study selection. 2.3.2 Study characteristics Error! Reference source not found. shows the key characteristics for each cohort included in the meta-analysis, structured by outcome, and ordered by ROB from low to high risk. More detail is available in supplementary table 3. All studies were published from 2013 onwards. Six cohorts were based in the USA, three from European countries, and one from each of Canada, Japan, China, Mexico, Australia, and New Zealand. Cohort sizes ranged from 176 to 6795

participants (average 2036). All participants were older adults at baseline with a mean age ranging from 65 to 84.6 years (average 76 years). Gait speed was assessed using a stopwatch in most studies other than the three which reported on cohorts that used a computerized walkway. 4,5,8 The measuring distance ranged from 2.4 to 6 meters and most cohorts measured usual walking speed, although two studies measured maximum walking speed. 10,46 Slow gait was defined as one standard deviation or more below age- and sex-matched means in the population in all but two cohorts, one of which classed as slow walkers all those walking <0.8 meters per second (or < 0.66 meters per second if female less than 1.45m in height)¹⁶ and the other which classed as slow walkers all those in the lowest 20th percentile of the cohort population.⁴⁷ Subjective cognitive complaint was measured using different methods in different cohorts, such as the memory item from the 15-item Geriatric Depression Scale, 8,10,11,15,17,44,46 the eight-item informant interview (AD8), 17 the Clinical Dementia Rating scale, 17 the 15-item Consortium to Establish a Registry for Alzheimer's Disease (CERAD) questionnaire. 4 Of note, studies on the EPIDOS cohort included in this review and meta-analysis used an objective measure of cognitive complaint, namely any incorrect responses on the Short Portable Mental Status Questionnaire (SPMSQ). Accordingly, results should be treated with caution. 9,13,15 In other studies, a positive response from participants to a question such as "Is your memory worse than 10 years ago?" was sufficient.12

2.3.3 Results of ROB assessments

419

420

421

422

423

42.4

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

Figure 2 contains a summary ROB of the pooled studies (top) as well as a traffic-light plot (bottom) showing the ROB of the individual studies, assessed against the nine domains. In the pooled summary, the domains with highest ROB were due to missing data, exposure variable measurement, confounding and generalizability. In the traffic-light plot, there was a high ROB in at least one domain in the majority (7/11) of studies, and all studies contained at least one

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

domain judged as being of some concern. Overall, six studies had low ROB, four studies had some concerns, and one study had a high ROB. 2.3.4 Meta-analysis of health outcomes predicted by MCR The meta-analysis findings are summarized in the forest plots and described in more detail below (figure 3). Dementia We combined six cohorts from four studies that examined dementia as an outcome, totaling 9,955 participants. 4,5,11,45 Four cohorts were from two studies with a low ROB 4,5 and two were from studies with a moderate risk of overall bias. 11,45 Individuals with MCR at baseline were over twice as likely to develop dementia compared to those without MCR, over an average follow-up of 4.3 years (aHR 2.12, 95%CI 1.85-2.42, p<0.0001, $I^2=33.1\%$, $tau^2=<0.0001$, prediction interval 1.75-2.56). Cognitive Impairment Six cohorts from three studies, including a total of 6,458 participants, reported on cognitive impairment as an outcome. Five cohorts were from two studies with a low risk of overall bias^{5,16} and one⁴⁷ with a moderate risk of overall bias. Those with MCR at baseline were at an increased risk of developing cognitive impairment compared to those without MCR, over an average follow-up of 5.6 years (aHR 1.76, 95%CI 1.49-2.08, p<0.0001, I^2 =24.9%, tau^2 =0.0095, prediction interval 1.23-2.52).

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

Falls

We combined eight cohorts from three studies, including a total of 12,640 participants with falls as an outcome. Two cohorts were from one study with a high risk of overall bias, mainly due to this study's small sample size and method of dealing with confounders. 10 These cohorts were weighted in the meta-analysis in accordance with their results imprecision, so their effect on the overall result was minimal (combined weighting of 6.3%). One cohort was from a study with a moderate ROB,9 while the other five cohorts were from a study with a low ROB.8 Those with MCR at baseline were at a 38% relative risk increase of falls compared to those without MCR (aRR 1.38, 95%CI 1.15-1.66, p=0.0005, I^2 =62.1%, tau²=0.039, prediction interval 0.91-2.36). The average follow-up of all cohorts was 1.4 years. A subgroup analysis excluding the two cohorts with a high risk of overall bias (total n=478 participants) made no difference to the effect measure of prognostic ability for MCR at baseline with falls on follow-up (aRR 1.38, 95%CI 1.14-1.69, p=0.0013, $I^2=70.2\%$, tau²=0.043, prediction interval 0.73-2.63). Mortality Four cohorts from two studies, including 19,818 participants, reported on mortality as an outcome. Three of these came from a study with a low risk of overall bias, 12 with the other study¹³ having a moderate risk of overall bias. Those with MCR at baseline were at an increased risk of mortality compared to those without MCR, over an average follow-up of 5.3 years (aHR 1.49, 95%CI 1.16-1.91, p<0.0001, $I^2=79.2\%$, $tau^2=0.0477$, prediction interval 0.50-4.42). 2.3.5 Bias of studies or outcomes included in the meta-analysis On visual inspection of the funnel plots, both the dementia and cognitive impairment outcomes appear to be missing smaller studies with a smaller effect size (figure 4). As there are fewer than ten studies for each outcome, any test for funnel plot asymmetry will have low power for

distinguishing chance from real asymmetry. 40 Nonetheless, the results from Egger's test did not support asymmetry for dementia (p=0.15), cognitive impairment (p=0.06), falls (p=0.69) or mortality (p=0.54).

There was no evidence of selective non-reporting of results from any of the studies included in this review or meta-analysis.

3. Further detail on methods and results

3.1 Further methodological details

3.1.2 Quality assessment of included studies

Prior to ROB assessment, two authors (DM and AC) independently evaluated the methodological quality of the selected studies using a customized quality assessment tool that builds on the 14 criteria of the Cochrane recommended National Institute for Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.⁴⁹ An additional 15 criteria from the Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines⁵⁰ were added to our tool, resulting in a total of 29 criteria by which each study was assessed (supplementary table 4). Two authors independently rated each study quality overall as "high" if most criteria were met and there was little risk of bias (ROB), "satisfactory" if most criteria were met with some flaws in the study, or "low" when most criteria were not met, and/or there were significant flaws relating to key aspects of study design. Any discrepancies in judgements were resolved by discussion to reach a consensus. There were no discrepancies in our independent overall impression of each study. Our approach fits with that recommended by the Cochrane Handbook v6.2.⁴⁰

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

In addition to this detailed quality assessment, we performed a more succinct ROB assessment as described in section 1.5.5. From the criteria in our quality assessment tool, we selected those most relevant to ROB: (i) bias due to lack of study focus; (ii) bias arising from cohort used; (iii) bias due to MCR measurement; (iv) bias due to outcome measurement; (v) bias due to missing data; (vi) bias due to confounding; (vii) bias due to follow-up; (viii) bias due to results precision; (ix) bias due to lack of generalizability. These criteria are more appropriate when assessing ROB of studies describing a syndrome such as MCR than the recently developed Prediction model Risk Of Bias ASsessment Tool (PROBAST) tool, 51 which assesses multivariable prediction models. The risk of bias plots were created in the coding language R using the "robvis (0.3.0.9)" package.⁵² The code syntax is openly available on GitHub (https://github.com/dmullin?tab=repositories). 3.1.2 Assessment of certainty in the body of evidence We assessed the certainty of the body of evidence for MCR as a predictor of each outcome in the meta-analysis against the GRADE considerations adapted for prognosis research as recommended by Huguet⁴³, see section 1.6.5. We graded the certainty in the results for MCR as a predictor of dementia, cognitive impairment, falls, and mortality as low (see table 2). This low certainty is typical for prognosis research using even sound observational studies. 40 The seven GRADE criteria considered, and our impressions for each, are described in supplementary box 2 of the appendix. 3.2 Further results 3.2.1 Studies excluded from meta-analysis A further two eligible studies 15,46 reported on MCR as a predictor of dementia and two more as a predictor of cognitive impairment^{17,44} but, due to how the effect size was reported in each, (e.g.,

reporting OR rather than HR) we were unable to include them in our meta-analysis. Despite correspondence with study authors, we did not obtain the data necessary to allow calculation of the effect measure used in our meta-analysis. Reassuringly, these excluded studies share similar characteristics and direction of effect size to those included in the meta-analysis (table 3). They were judged as having either a moderate or high ROB. The effect precision was poor in three of the studies and not reported in the other, so if it had been possible to include these in the metaanalysis, they would have had a relatively small weighting and therefore, a minimal impact on the overall result. MCR at baseline was reported to predict other health outcomes on follow-up, but there were not enough different cohorts reporting on the same outcomes to allow for meta-analysis. One study found that MCR was a predictor of incident disability after 2.5 years (aHR 2.25 (1.39-3.67) p=0.001). Disability was defined as a primary care doctor evaluated need for new long-term care insurance certification. Another study, already included in our meta-analysis for falls at one year, also reported on MCR as a predictor of recurrent falls, defined as two or more falls, (aHR 1.46 (1.04-2.05) p=0.030) and of post-falls hip fractures (aHR 2.54 (1.78-3.63) p \leq 0.001).

Research in Context

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

Systematic review: We systematically retrieved and reviewed the literature using traditional sources and correspondence with authors. While the predictive value of MCR for cognitive impairment, dementia, falls, and mortality have been reported in sufficient cohorts to allow for meta-analysis, other outcomes such as disability were not, so were reported in narrative form.

564

565

566

567

568

569

570

571

572573

574

575

576

577

578

579

580

581

582

583

Interpretation: Our findings led to an integrated hypothesis describing the pathophysiology of MCR. This hypothesis is consistent with epidemiological, imaging, and genetic findings currently in the public domain. Future directions: This manuscript proposes a framework for the generation of new hypotheses and describes a roadmap to validate these hypotheses. Examples include: (a) clarifying the definition of subjective cognitive complaint; (b) longitudinal studies with biomarkers and pathological analysis; (c) genome wide association studies of MCR to identify genetic polymorphisms and potential treatment targets of interest. Correspondence Dr Donncha S. Mullin, Division of Psychiatry, University of Edinburgh, Kennedy Tower, Royal Edinburgh Hospital, Morningside Terrace, Edinburgh, EH10 5HF, UK Telephone: +44 (0)131 537 6000; Email: <u>D.Mullin@ed.ac.uk</u> Acknowledgements Ruth Jenkins, academic support librarian at the University of Edinburgh, helped with search terms and recommending databases. Dr Sue Lord, Lecturer at the Auckland University of Technology, New Zealand, supplied raw data from her study to allow for calculation of appropriate effect measure.

REFERENCES

584

- 586 1. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimer's Dement.* 2015;11(1):70-98. doi:10.1016/J.JALZ.2014.04.514
- Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry. 2007;78(9):929-935.
 doi:10.1136/jnnp.2006.106914
- Ayers E, Verghese J. Gait Dysfunction in Motoric Cognitive Risk Syndrome. Montero-Odasso M, Perry G, eds. J Alzheimer's Dis. 2019;71(s1):S95-S103. doi:10.3233/JAD-181227
- Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk
 of dementia. Journals Gerontol Ser A Biol Sci Med Sci. 2013;68(4):412-418.
 doi:10.1093/gerona/gls191
- 598 5. Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: Multicountry 599 prevalence and dementia risk. *Neurology*. 2014;83(8):718-726. 600 doi:10.1212/WNL.000000000000717
- 601 6. Meiner Z, Ayers E, Verghese J. Motoric cognitive risk syndrome: A risk factor for cognitive impairment and dementia in different populations. *Ann Geriatr Med Res.* 2020;24(1):3-14. doi:10.4235/agmr.20.0001
- Sekhon H, Allali G, Launay CP, et al. Motoric cognitive risk syndrome, incident cognitive impairment and morphological brain abnormalities: Systematic review and meta-analysis.
 Maturitas. 2019;123(February):45-54. doi:10.1016/j.maturitas.2019.02.006
- 607 8. Callisaya ML, Ayers E, Barzilai N, et al. Motoric Cognitive Risk Syndrome and Falls Risk: 608 A Multi-Center Study. Montero-Odasso M, ed. *J Alzheimer's Dis.* 2016;53(3):1043-1052. 609 doi:10.3233/JAD-160230
- Beauchet O, Sekhon H, Schott A-MM, et al. Motoric Cognitive Risk Syndrome and Risk for Falls, Their Recurrence, and Postfall Fractures: Results From a Prospective
 Observational Population-Based Cohort Study. J Am Med Dir Assoc. 2019;20(10):1268-1273. doi:10.1016/j.jamda.2019.04.021
- Lord S, Moyes S, Teh R, et al. Gait, cognition and falls over 5 years, and motoric
 cognitive risk in New Zealand octogenarians: Te Puāwaitanga o Nga Tapuwae Kia Ora
 Tonu, LiLACS NZ. BMC Geriatr. 2020;20(1):1-8. doi:10.1186/s12877-020-1420-8
- Doi T, Shimada H, Makizako H, et al. Motoric Cognitive Risk Syndrome: Association with Incident Dementia and Disability. J Alzheimer's Dis. 2017;59(1):77-84.
 doi:10.3233/JAD-170195
- Ayers E, Verghese J. Motoric cognitive risk syndrome and risk of mortality in older adults.

 Alzheimer's Dement. 2016;12(5):556-564. doi:10.1016/j.jalz.2015.08.167
- 622 13. Beauchet O, Sekhon H, Launay CP, et al. Motoric cognitive risk syndrome and mortality: 623 results from the EPIDOS cohort. *Eur J Neurol.* 2019;26(5):794-e56. 624 doi:10.1111/ene.13891
- Semba RD, Tian Q, Carlson MC, Xue Q-LL, Ferrucci L. Motoric cognitive risk
 syndrome: Integration of two early harbingers of dementia in older adults. Ageing Res Rev.
 2020;58(January):101022. doi:10.1016/j.arr.2020.101022
- 628 15. Beauchet O, Sekhon H, Launay CP, Rolland Y, Schott AM, Allali G. Motoric cognitive 629 risk syndrome and incident dementia: results from a population-based prospective and 630 observational cohort study. *Eur J Neurol.* 2020;27(3):468-474. doi:10.1111/ene.14093
- 631 16. Aguilar-Navarro SG, Mimenza-Alvarado AJ, Aguilar-Esquivel JE, Yeverino-Castro SG, 632 Juarez-Cedillo T. Motoric Cognitive Risk Syndrome: Prevalence and Risk of Cognitive
- 633 Impairment in a Population Studied in the Mexican Health and Aging Study 2012–2015. *J*634 *Nutr Heal Aging*. 2019;23(3):227-231. doi:10.1007/s12603-019-1160-7

- Allali G, Ayers EI, Verghese J. Motoric Cognitive Risk Syndrome Subtypes and Cognitive Profiles. *Journals Gerontol Ser A Biol Sci Med Sci.* 2016;71(3):378-384.
 doi:10.1093/gerona/glv092
- 638 18. Sekhon H, Allali G, Beauchet O. The association of anxio-depressive disorders and
 639 depression with motoric cognitive risk syndrome: results from the baseline assessment of
 640 the Canadian longitudinal study on aging. GeroScience. 2019;41(4):409-418.
 641 doi:10.1007/s11357-019-00093-z
- Stephan Y, Sutin AR, Canada B, Terracciano A. Personality and Motoric Cognitive Risk
 Syndrome. J Am Geriatr Soc. 2020;68(4):803-808. doi:10.1111/jgs.16282
- Khachaturian ZS, Kuller LH, Khachaturian AS. Strategic goals and roadmap for dementia
 prevention by stroke prevention. *Alzheimer's Dement*. 2019;15(7):865-869.
 doi:10.1016/j.jalz.2019.06.003
- Hachinski V, Einhäupl K, Ganten D, et al. Preventing dementia by preventing stroke: The Berlin Manifesto. *Alzheimer's Dement.* 2019;15(7):961-984. doi:10.1016/j.jalz.2019.06.001
- Wang N, Allali G, Kesavadas C, et al. Cerebral Small Vessel Disease and Motoric
 Cognitive Risk Syndrome: Results from the Kerala-Einstein Study. J Alzheimer's Dis.
 2016;50(3):699-707. doi:10.3233/JAD-150523
- Nadkarni NK, Perera S, Snitz BE, et al. Association of brain amyloid-β with slowgait in elderly individuals without dementia influence of cognition and apolipoprotein e 24
 genotype. JAMA Neurol. 2017;74(1):82-90. doi:10.1001/jamaneurol.2016.3474
- Cohen JA, Verghese J, Zwerling JL. Cognition and gait in older people. *Maturitas*.
 2016;93:73-77. doi:10.1016/j.maturitas.2016.05.005
- 657 25. Beauchet O, Sekhon H, Barden J, et al. Association of motoric cognitive risk syndrome 658 with cardiovascular disease and risk factors: Results from an original study and meta-659 analysis. J Alzheimer's Dis. 2018;64(3):875-887. doi:10.3233/JAD-180203
- Sathyan S, Wang T, Ayers E, Verghese J. Genetic basis of motoric cognitive risk
 syndrome in the Health and Retirement Study. Neurology. 2019;92(13):E1427-E1434.
 doi:10.1212/WNL.0000000000007141
- Donini LM, Savina C, Gennaro E, et al. A systematic review of the literature concerning the relationship between obesity and mortality in the elderly. *J Nutr Heal aging 2012 161*. 2011;16(1):89-98. doi:10.1007/S12603-011-0073-X
- G R Neri S, S Oliveira J, B Dario A, M Lima R, Tiedemann A. Does Obesity Increase the
 Risk and Severity of Falls in People Aged 60 Years and Older? A Systematic Review and
 Meta-analysis of Observational Studies. *Journals Gerontol Ser A*. 2020;75(5):952-960.
 doi:10.1093/GERONA/GLZ272
- Sathyan S, Barzilai N, Atzmon G, Milman S, Ayers E, Verghese J. Association of anti-inflammatory cytokine IL10 polymorphisms with motoric cognitive risk syndrome in an Ashkenazi Jewish population. *Neurobiol Aging*. 2017;58:238.e1-238.e8.
 doi:10.1016/j.neurobiolaging.2017.06.006
- 674 30. P C, A L, C C-D, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque 675 burden and worsening cognitive behavior. *Neuron*. 2015;85(3):519-533. 676 doi:10.1016/J.NEURON.2014.11.020
- Verghese J, Holtzer R, Wang C, Katz MJ, Barzilai N, Lipton RB. Role of APOE genotype
 in gait decline and disability in aging. *Journals Gerontol Ser A Biol Sci Med Sci*.
 2013;68(11):1395-1401. doi:10.1093/gerona/glt115
- Wirths O, Bayer TA. Motor impairment in Alzheimer's disease and transgenic
 Alzheimer's disease mouse models. Authors J Compil #. 2008;7:1-5. doi:10.1111/j.1601-183X.2007.00373.x
- Ayers E, Verghese J. Diagnosing motoric cognitive risk syndrome to predict progression to dementia. *Neurodegener Dis Manag.* 2014;4(5):339-342. doi:10.2217/nmt.14.39
- 685 34. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated

- 686 guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1186/s13643-021-687 01626-4
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in
 Epidemiology A Proposal for Reporting. JAMA. 2000;15:2008-2012.
 doi:10.1001/jama.283.15.2008
- McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer
 Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol.
 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021
- Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. *BMJ*. 2019;364. doi:10.1136/bmj.k4597
- 696 38. Covidence systematic review software. Accessed August 24, 2021. 697 https://support.covidence.org/help/how-can-i-cite-covidence
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8.
 doi:10.1186/1745-6215-8-16
- Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions
 | Cochrane Training. Vol 6.2. 6.2.; 2021. Accessed April 15, 2021.
 https://training.cochrane.org/handbook/current
- 704 41. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis in R: A Hands-on Guide; 2019. doi:10.5281/zenodo.2551803
- 706 42. Viechtbauer W, Wolfgang V. Conducting meta-analyses in R with the metafor package. J 707 Stat Software, 2010;36(3):1-48. http://www.jstatsoft.org/
- Huguet A, Hayden JA, Stinson J, et al. Judging the quality of evidence in reviews of prognostic factor research: Adapting the GRADE framework. Syst Rev. 2013;2(1).
 doi:10.1186/2046-4053-2-71
- Heauchet O, Sekhon H, Launay CP, Gaudreau P, Morais JAJA, Allali G. Relationship
 between motoric cognitive risk syndrome, cardiovascular risk factors and diseases, and
 incident cognitive impairment: Results from the "NuAge" study. *Maturitas*.
 2020;138(May):51-57. doi:10.1016/j.maturitas.2020.05.007
- 715 45. Beauchet O, Sekhon H, Cooper-Brown L, et al. Motoric cognitive risk syndrome and 716 incident dementia in older adults from the Québec NuAge cohort. *Age Ageing*. Published 717 online November 17, 2020. doi:10.1093/ageing/afaa235
- Kumai K, Meguro K, Kasai M, et al. Neuroepidemiologic and Neurobehavioral
 Characteristics of Motoric Cognitive Risk Syndrome in an Old-Old Population: The
 Kurihara Project. Dement Geriatr Cogn Dis Extra. 2016;6(2):176-182.
 doi:10.1159/000445539
- 47. Liu Y, Wei K, Cao X, et al. Development and Validation of a Nomogram Based on
 Motoric Cognitive Risk Syndrome for Cognitive Impairment. Front Aging Neurosci.
 2021;13:618833. doi:10.3389/fnagi.2021.618833
- 725 48. Chhetri JK, Zheng Z, Xu X, Ma C, Chan P. The prevalence and incidence of frailty in 726 Pre-diabetic and diabetic community-dwelling older population: Results from Beijing 727 longitudinal study of aging II (BLSA-II). *BMC Geriatr*. 2017;17(1). doi:10.1186/s12877-728 017-0439-y
- 729 49. Study Quality Assessment Tools | NHLBI, NIH. Accessed April 15, 2021. 730 https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
- Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of
 Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS
 Med. 2007;4(10):1628-1654. doi:10.1371/journal.pmed.0040297
- Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. *Ann Intern Med.* 2019;170(1):51-58.
 doi:10.7326/M18-1376

52. McGuinness L. robvis: An R package and web application for visualising risk-of-bias assessments. Published online 2019.

737

738

- 740 Table 1 Characteristics of studies
- 741 Table 2 GRADE assessment of certainty in results
- 742 Table 3 Excluded studies

744 Table 1 Characteristics and results of the studies included in the meta-analysis (further details in supplementary table 3)

Stu d y	Size	MCR prevalence %	Age mean years	Result (95% CI)
Doi et al. (2017)	4235	6.3	72	2.49 (1.52, 4.1) p<0.001
Verghese et al. (2013)	767	6.8	79.9	2.72 (1.24, 5.97) p=0.013
Verghese et al. (2014a1i)	1280	13	79.9	2.1 (1.43, 2.09)
Verghese et al. (2014a2i)	1013	13	75.1	1.98 (1.44, 2.74)
Verghese et al. (2014a3i)	1562	9	72.3	1.79 (1.31, 2.44)
Beauchet et al. (2020c)	1098	4.2	73.8	5.18 (2.43, 11.03) p≤0.001

MCR as a predictor of Cognitive Impairment

Stu dy	Size	MCR prevalence %	Age mean years	Result (95% CI)	
Aguilar-Navarro et al. (2019)	726	14.3	69.8	2.46 (1.25, 4.84) p=0.009	
Verghese et al. (2014a1)	1280	13	79.9	1.49 (1.08, 2.07) p=0.015	
Verghese et al. (2014a2)	1013	13	75.1	1.9 (1.44, 2.51) p=0.001	
Verghese et al. (2014a3)	1562	9	72.3	1.48 (1.16, 1.88) p=0.002	
Verghese et al. (2014a4)	700	8	74.1	2.74 (1.54, 4.86) p=0.001	
Liu et al. (2021)	1177	6.7	65	1.95 (1.21, 2.82)	

MCR as a predictor of Falls

Stu dy	Size	MCR prevalence %	Age mean years	Result (95% CI)
Callisaya et al. (2016a1)	509	11	75	1.06 (0.74, 1.52)
Callisaya et al. (2016a2)	817	12.1	79.7	1.18 (0.93, 1.49)
Callisaya et al. (2016a3)	3640	6.7	74.4	1.37 (1.18, 1.58)
Callisaya et al. (2016a4)	832	6.9	73.5	1.78 (1.23, 2.55)
Callisaya et al.	406	1.7	72	2.15 (1.57, 2.94)

(2016a5)					
Beauchet et al. (2019b)	5958	9.9	80.2	1.18 (1.02, 1.36)	
Lord et al. (2020a1)	302	1.9	84.6	1.67 (0.86, 3.23)	
Lord et al. (2020a2)	176	4.3	82.6	0.46 (0.07, 2.83)	

MCR as a predictor of Mortality

Stu dy	Size	MCR prevalence %	Age mean years	Result (95% CI)
Ayers and Verghese (2016a1)	4686	8	74.7	1.87 (1.54, 2.28)
Ayers and Verghese (2016a2)	6795	6.4	77.3	1.62 (1.21, 2.16)
Ayers and Verghese (2016a3)	4559	7	81.7	1.5 (1.04, 2.16)
Beauchet et al. (2019a)	3778	10.1	80.5	1.09 (0.89, 1.34) p=0.401

Note: Results are adjusted hazard ratios except for those cohorts with falls as the outcome, which are adjusted relative risk. MCR (Motoric Cognitive Risk); CI (Confidence Interval)

Table 2: GRADE assessment of certainty in the body of evidence for MCR as a predictor of each health outcome

748

751

752 753

754 755 Participants and setting: Longitudinal cohort studies of older adults in community settings Exposure: MCR or both of its components, objective slow gait speed and subjective cognitive complaint Comparator: a non-MCR group

Outcomes & Effect size (95%CI)	No.	Phase	ROB	Inconsist.	Imprecis.	Indirect.	Pub. bias	Effect size	GRADE certainty of evidence
Dementia aHR 2.12 (1.85-2.42)	9955								⊕⊕22 Low
Cognitive Impairment aHR 1.76 (1.49-2.08)	6458								⊕⊕22 Low
Falls aRR 1.38 (1.15-1.66)	12640	\bigcirc							⊕⊕22 Low
Mortality aHR 1.49 (1.16-1.91)	19818								⊕⊕22 Low

Note: aHR (adjusted hazard ratio); aRR (adjusted relative risk); No. (Number of participants in pooled meta-analysis for each outcome); Phase (Phase of Investigation); ROB (Risk of Bias); Inconsist. (Inconsistency); Imprecis. (Imprecision); Indirect. (Indirectness); Pub. Bias (Publication Bias)

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate — the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited — the true effect may be substantially different from the estimate of the effect.

Table 3 Characteristics of studies excluded from meta-analysis due to incompatible effect measures or lack of similar studies


Incompati	Incompatible effect measures											
Stu dy	Outcome	Country	Cohort	Size	Female %	MCR prevalence	Ag e m ean years	Time years	Result (95% CI)	ROB		
Beauchet et al. (2020a)	Dementia	France	EPIDOS	651	100	13.5*	79.5	7	aOR 2.07 (1.06-4.02) p=0.033	Mod.		
Kumai et al. (2016)	Dementia	Japan	Kurihara	516	61	11.1	79.8	4	aOR 1.38 (NR)	High		
Allali et al. (2016)	Cognitive Impairment	USA	CCMA	314	32	8	79.4	2	aOR 3.59 (1.30-10.10) p=0.016	Mod.		
Beauchet et al. (2020b)	Cognitive Impairment	Canada	NuAGE	1113	51.9	4.2	73.8	3	aOR 5.16 (CI 2.20- 12.08) p≤0.001	Mod.		

Lack of similar studies


Study	Outcome	Country	Cohort	Size	Female %	MCR prevalence	Age mean years	Time years	Result (95% CI) p-value	ROB
Doi 2017	Disability	Japan	OSHPE	4235	50	6.3	72	2.5	aHR 2.25 (1.39-3.67) p=0.001	Low
Beauchet 2019b	Falls recurrence (>=2)	France	EPIDOS	5958	100	9.9	80.2	4	aHR 1.46 (1.04-2.05) p=0.030	Mod.
Beauchet 2019b	Post-fall hip fractures	France	EPIDOS	5958	100	9.9	80.2	4	aHR 2.54 (1.78-3.63) p≤0.001	Mod.

Note: *MCR prevalence is different to that reported in the study abstract as we calculated 88 / 651 had MCR (47 slowed walking, 41 slowed walking and slowed five-times sit-to-stand).

MCR (Motoric Cognitive Risk); CI (Confidence Interval); ROB (Risk of Bias); aOR (adjusted odds ratio); aHR (adjusted hazards ratio); HR (hazard ratio); NR (not reported); CCMA (Central Control of Mobility in Aging); OSHPE (Obu Study of Health Promotion for the Elderly); NuAGE (Quebec Longitudinal Study on Nutrition and Successful Aging); EPIDOS (Epidemiologie de l'Osteoporose);



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/



		Risk of bias domains											
		D1	D2	D3	D4	D5	D6	D7	D8	D9	Overall		
	Aguilar-Navarro 2019	-	-	-	+	-	+	X	+	+	+		
	Ayers 2016	+	+	+	+	-	+	-	+	-	+		
	Beauchet 2019a	+	+	-	+	-	+	+	+	X	-		
	Beauchet 2019b	+	+	-	+	-	+	+	+	X	-		
	Beauchet 2020c	+	-	+	-	-	X	+	X	-	-		
Study	Callisaya 2016	+	+	+	+	-	+	+	+	+	+		
	Doi 2017	+	+	+	+	+	+	-	+	-	+		
	Liu 2021	-	+	-	+	+	X	+	+	-	-		
	Lord 2020	-	+	-	-	+	X	+	-	-	X		
	Verghese 2013	+	+	+	+	-	+	+	+	+	+		
	Verghese 2014	+	+	+	+	X	+	+	+	+	+		

D1: Bias due to study focus

D2: Bias due to cohort

D3: Bias due to MCR measurement

D4: Bias due to outcome measurement

D5: Bias due to missing data

D6: Bias due to confounding

D7: Bias due to follow-up
D8: Bias due to results precision

D9: Bias due to generalisability

Judgement

High Unclear + Low

